Clifford R. Jack

TL;DR: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics and the CSF measures heralded progression of clinical measures over 12 months.

TL;DR: There is increasing evidence that a combination of currently existing neuroimaging and cerebrospinal fluid (CSF) and blood biomarkers can provide important complementary information and thus contribute to a more accurate and earlier diagnosis of AD.

TL;DR: The major accomplishments of ADNI have been the development of standardized methods for clinical tests, magnetic resonance imaging, positron emission tomography (PET), and cerebrospinal fluid (CSF) biomarkers in a multicenter setting, and the improvement of clinical trial efficiency.

TL;DR: Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects, and ADNI provides significant new information concerning the progression of AD.

TL;DR: The Clinical Core of the Alzheimer's Disease Neuroimaging Initiative has provided clinical, operational, and data management support to ADNI since its inception, and this article reviews the activities and accomplishments of the core in support of ADNI aims.